"Cholesterol, LDL" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol.
| Descriptor ID |
D008078
|
| MeSH Number(s) |
D04.210.500.247.808.197.244 D10.532.515.500 D10.570.938.208.275 D12.776.521.550.500
|
| Concept/Terms |
Cholesterol, LDL- Cholesterol, LDL
- Low Density Lipoprotein Cholesterol
- beta-Lipoprotein Cholesterol
- Cholesterol, beta-Lipoprotein
- beta Lipoprotein Cholesterol
- LDL Cholesterol
|
Below are MeSH descriptors whose meaning is more general than "Cholesterol, LDL".
Below are MeSH descriptors whose meaning is more specific than "Cholesterol, LDL".
This graph shows the total number of publications written about "Cholesterol, LDL" by people in this website by year, and whether "Cholesterol, LDL" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 3 | 3 |
| 1996 | 0 | 1 | 1 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 3 | 3 |
| 2003 | 1 | 6 | 7 |
| 2004 | 1 | 2 | 3 |
| 2005 | 1 | 2 | 3 |
| 2006 | 2 | 2 | 4 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 3 | 3 |
| 2010 | 2 | 6 | 8 |
| 2011 | 2 | 4 | 6 |
| 2012 | 1 | 2 | 3 |
| 2013 | 0 | 2 | 2 |
| 2014 | 3 | 4 | 7 |
| 2015 | 1 | 2 | 3 |
| 2016 | 2 | 6 | 8 |
| 2017 | 3 | 4 | 7 |
| 2018 | 1 | 2 | 3 |
| 2019 | 1 | 3 | 4 |
| 2020 | 4 | 3 | 7 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 6 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cholesterol, LDL" by people in Profiles.
-
Lipoprotein(a) and LDL-C: The Relevance of Equivalence. J Am Coll Cardiol. 2022 11 22; 80(21):2011-2013.
-
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022 10 04; 80(14):1366-1418.
-
Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes. J Clin Lipidol. 2022 Sep-Oct; 16(5):747-756.
-
Current and emerging drugs for the treatment of atherosclerosis: the evidence to date. Expert Rev Cardiovasc Ther. 2022 Jul; 20(7):515-527.
-
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. Circulation. 2022 Aug 30; 146(9):657-672.
-
Statin-associated muscle symptoms-A review: Individualizing the approach to optimize care. Pharmacotherapy. 2022 05; 42(5):428-438.
-
Gender differences in comorbidities and risk factors in ischemic stroke patients with a history of atrial fibrillation. BMC Neurol. 2021 May 25; 21(1):209.
-
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J. 2020 11 21; 41(44):4245-4255.
-
Joint effect of race/ethnicity or location of residence and sex on low density lipoprotein-cholesterol among veterans with type 2 diabetes: a 10-year retrospective cohort study. BMC Cardiovasc Disord. 2020 10 15; 20(1):449.
-
Identifying hotspots of cardiometabolic outcomes based on a Bayesian approach: The example of Chile. PLoS One. 2020; 15(6):e0235009.